Michael D. Wendt
Protein-Protein Interactions as Drug Targets
Shaomeng Wang, Yujun Zhao, Denzil Bernard, Angelo Aguilar, Sanjeev Kumar
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics
Kurt Deshayes, Jeremy Murray, Domagoj Vucic
The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer
John F. Kadow, David R. Langley, Nicholas A. Meanwell, Michael A. Walker, Kap-Sun Yeung, Richard Pracitto
Protein-Protein Interaction Targets to Inhibit HIV-1 Infection
Nicholas A. Meanwell, David R. Langley
Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion - a Focus on Respiratory Syncytial Virus
Andrew B. Mahon, Stephen E. Miller, Stephen T. Joy, Paramjit S. Arora
Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces
Michael D. Wendt
The Discovery of Navitoclax, a Bcl-2 Family Inhibitor
Table of Contents:
Protein-Protein Interactions as Drug Targets.- Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics.- The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer.- Protein-Protein Interaction Targets to Inhibit HIV-1 Infection.- Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion – a Focus on Respiratory Syncytial Virus.- Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces.- The Discovery of Navitoclax, a Bcl-2 Family Inhibitor.
